indomethacin has been researched along with Necrotizing Enterocolitis in 59 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of indomethacin as a tocolytic agent for preterm labor is associated with an increased risk for severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia." | 8.91 | Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis. ( Hammers, AL; Kaunitz, AM; Sanchez-Ramos, L, 2015) |
| "To determine if intestinal perforations before 14 days (either spontaneous (SIP) or necrotizing enterocolitis-induced) are increased when infants who received antenatal betamethasone shortly before birth are treated with prophylactic indomethacin (PINDO)." | 8.31 | Prophylactic indomethacin, antenatal betamethasone, and the risk of intestinal perforation in infants <28 weeks' gestation. ( Clyman, RI; Hills, NK, 2023) |
| "Postnatal indomethacin is reportedly associated with an increased incidence of necrotizing enterocolitis (NEC) in preterm infants." | 7.77 | The risk of necrotizing enterocolitis after indomethacin tocolysis. ( Holzhausen, KA; Kellogg, H; Lulic-Botica, M; Pruder, S; Salari, V; Sood, BG; Thomas, R, 2011) |
| "To examine the ontogeny of salivary epidermal growth factor (sEGF) in premature infants and to determine the relation of sEGF to the development of necrotizing enterocolitis (NEC)." | 7.74 | Ontogeny of salivary epidermal growth factor and necrotizing enterocolitis. ( Erwin, CR; Leonard, AC; Ryan, AL; Seeger, K; Warner, BB; Warner, BW, 2007) |
| "A retrospective study to compare the incidence of NEC, NEC-related gastrointestinal complications and isolated gastrointestinal perforation among premature infants treated for a PDA with either, indomethacin alone (I), surgical ligation alone (L), or indomethacin followed by surgical ligation (I-L)." | 7.72 | Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus. ( Adams, JM; Adams, K; Baetiong, A; Chen, A; O'Donovan, DJ; Smith, EO; Weisman, LE, 2003) |
| "Tocolysis with indomethacin as a single agent was not associated with necrotizing enterocolitis in this case-control study." | 7.70 | Indomethacin tocolysis and risk of necrotizing enterocolitis. ( Dooley, SL; Grobman, WA; Holtzman, RB; Parilla, BV; Thomas, HA, 2000) |
| "(2) Multiple analyses showed that patent ductus arteriosus(PDA) (odds ratio[OR] = 5." | 5.91 | Patent ductus arterious and increased conjugated bilirubin in the second week after birth are independent risk factors for necrotizing enterocolitis in preterm infants: an observational study. ( Cui, S; Han, X, 2023) |
| "Expectant management for PDA in extremely premature infants was noninferior to early ibuprofen treatment with respect to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks' postmenstrual age." | 5.69 | Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. ( Avino, D; de Baat, T; De Bisschop, B; de Boode, WP; de Vries, WB; Derriks, F; Dijk, PH; Dijkman, KP; Donders, R; Henriksen, TB; Hocq, C; Hundscheid, T; Kooi, EMW; Kroon, AA; Kyng, KJ; Meeus, M; Mulder, AL; Mulder-de Tollenaer, SM; Nuytemans, DHGM; Onland, W; van Kaam, AH; Van Overmeire, B; Vijlbrief, DC; Villamor, E; Visser, R; Zecic, A, 2023) |
| "Indomethacin has been also used in women with short cervices as well as in those with idiopathic polyhydramnios." | 5.38 | Indomethacin in pregnancy: applications and safety. ( Abou-Ghannam, G; Nassar, AH; Usta, IM, 2012) |
| "The effect of patent ductus arteriosus on necrotizing enterocolitis was assessed using multiple regression analysis." | 5.33 | Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. ( Dollberg, S; Lusky, A; Reichman, B, 2005) |
| "Indomethacin use has been implicated as a co-risk factor for SIP when combined with glucocorticoids, but previous evidence argued against indomethacin being an independent risk factor when used prophylactically." | 5.33 | New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure. ( Attridge, JT; Clark, R; Gordon, PV; Walker, MW, 2006) |
| " We used the GRADE approach to assess the certainty of evidence for the following outcomes: failure of PDA closure within one week of administration of the first dose of indomethacin; bronchopulmonary dysplasia (BPD) at 28 days' postnatal age and at 36 weeks' postmenstrual age; proportion of infants requiring surgical ligation or transcatheter occlusion; all-cause neonatal mortality; necrotizing enterocolitis (NEC) (≥ Bell stage 2); and mucocutaneous or gastrointestinal bleeding." | 5.12 | Indomethacin for symptomatic patent ductus arteriosus in preterm infants. ( Evans, P; Flyer, JN; Mitra, S; O'Reilly, D; Soll, R, 2021) |
| " In view of this and with its higher incidence of necrotizing enterocolitis, we do not recommend using prolonged low-dose indomethacin for closing the patent ductus arteriosus in very low birth weight infants." | 5.10 | Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants. ( Lee, J; Leong, JY; Rajadurai, VS; Tan, KW; Wong, EH; Wong, KY, 2003) |
| "In extremely-low-birth-weight infants, prophylaxis with indomethacin does not improve the rate of survival without neurosensory impairment at 18 months, despite the fact that it reduces the frequency of patent ductus arteriosus and severe periventricular and intraventricular hemorrhage." | 5.09 | Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. ( Davis, P; Moddemann, D; Ohlsson, A; Roberts, RS; Saigal, S; Schmidt, B; Solimano, A; Vincer, M; Wright, LL, 2001) |
| " Moderate certainty evidence showed a reduction in NEC following administration of a combination of species of probiotics, probiotics (any), antenatal corticosteroids in pregnant women at risk of preterm birth, and ibuprofen versus indomethacin for treatment of patent ductus arteriosus (PDA)." | 5.05 | An Overview of Systematic Reviews of Randomized-Controlled Trials for Preventing Necrotizing Enterocolitis in Preterm Infants. ( Ei-Saie, A; Maheshwari, A; Neu, J; Pammi, M; Xiong, T, 2020) |
| "A high dose of oral ibuprofen was associated with a higher likelihood of hemodynamically significant PDA closure vs standard doses of intravenous ibuprofen or intravenous indomethacin; placebo or no treatment did not significantly change the likelihood of mortality, necrotizing enterocolitis, or intraventricular hemorrhage." | 4.98 | Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. ( Florez, ID; Mbuagbaw, L; Mitra, S; Sadeghirad, B; Tamayo, ME; Thabane, L; Vanniyasingam, T; Veroniki, AA; Zea, AM; Zhang, Y, 2018) |
| " Oral ibuprofen is associated with lower instance of necrotizing enterocolitis." | 4.95 | Patent Ductus Arteriosus in the Preterm Infant: Diagnostic and Treatment Options. ( Keim-Malpass, J; Prescott, S, 2017) |
| "The use of indomethacin as a tocolytic agent for preterm labor is associated with an increased risk for severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia." | 4.91 | Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis. ( Hammers, AL; Kaunitz, AM; Sanchez-Ramos, L, 2015) |
| "Antenatal indomethacin may be associated with an increased risk of periventricular leukomalacia and necrotizing enterocolitis in premature infants and therefore should be used judiciously for tocolysis." | 4.84 | Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes. ( Amin, SB; Glantz, JC; Sinkin, RA, 2007) |
| "To determine if intestinal perforations before 14 days (either spontaneous (SIP) or necrotizing enterocolitis-induced) are increased when infants who received antenatal betamethasone shortly before birth are treated with prophylactic indomethacin (PINDO)." | 4.31 | Prophylactic indomethacin, antenatal betamethasone, and the risk of intestinal perforation in infants <28 weeks' gestation. ( Clyman, RI; Hills, NK, 2023) |
| " Magnesium sulfate administration, steroid administration, maternal diabetes mellitus, gestational age at delivery, indomethacin exposure, birthweight, and chorioamnionitis were all considered as possible covariates in the multivariable regression models." | 3.83 | Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes. ( DeWitt, PE; Faucett, AM; Gibbs, RS; Metz, TD, 2016) |
| "To compare the incidence of medical closure of patent ductus arteriosus (PDA) and adverse events (acute renal dysfunction, necrotizing enterocolitis, spontaneous intestinal perforation, and gastrointestinal bleeding) between preterm infants who received indomethacin and ibuprofen for the treatment of PDA." | 3.79 | Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. ( Bali, V; Harabor, A; Kamaluddeen, M; Sivanandan, S; Soraisham, AS, 2013) |
| " Infants who had PDA and survived beyond 72 hours were included in multivariable logistic regression analyses that compared mortality or any severe neonatal morbidity (intraventricular hemorrhage grades ≥ 3, retinopathy of prematurity stages ≥ 3, bronchopulmonary dysplasia, or necrotizing enterocolitis stages ≥ 2) between treatment groups (conservative management, indomethacin only, surgical ligation only, or both indomethacin and ligation)." | 3.78 | Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. ( Allen, AC; Aziz, K; Lee, SK; Mirea, L; Ohlsson, A; Sankaran, K; Seshia, M; Shah, PS, 2012) |
| "In infants with VLBW, oral ibuprofen is as effective as intravenous indomethacin for closure of PDA and is associated with significantly fewer cases of necrotizing enterocolitis among infants with birth body weights <1250 g and significantly lower rates of elevated creatinine levels among neonates with birth body weights ranging from 1000 to 1500 g." | 3.78 | Oral ibuprofen versus intravenous indomethacin for closure of patent ductus arteriosus in very low birth weight infants. ( Chen, HN; Hsiao, CC; Lee, CH; Lee, ML; Tsao, LY, 2012) |
| "Postnatal indomethacin is reportedly associated with an increased incidence of necrotizing enterocolitis (NEC) in preterm infants." | 3.77 | The risk of necrotizing enterocolitis after indomethacin tocolysis. ( Holzhausen, KA; Kellogg, H; Lulic-Botica, M; Pruder, S; Salari, V; Sood, BG; Thomas, R, 2011) |
| "Diet, indomethacin, and early use of dexamethasone have been implicated as possible causes of necrotizing enterocolitis and intestinal perforation." | 3.74 | Prevention of necrotizing enterocolitis in preterm infants: a 20-year experience. ( Achanti, B; Lilien, L; Mehta, SK; Pietz, J; Stepka, EC, 2007) |
| "To examine the ontogeny of salivary epidermal growth factor (sEGF) in premature infants and to determine the relation of sEGF to the development of necrotizing enterocolitis (NEC)." | 3.74 | Ontogeny of salivary epidermal growth factor and necrotizing enterocolitis. ( Erwin, CR; Leonard, AC; Ryan, AL; Seeger, K; Warner, BB; Warner, BW, 2007) |
| "In this retrospective study, we tested the following hypotheses: rates of severe intraventricular hemorrhage (SIVH) and early neonatal survival are similar among extremely low birth weight (ELBW) infants treated with combination prophylaxis of phenobarbital and indomethacin compared with phenobarbital alone or no prophylaxis; and rates of patent ductus arteriosus (PDA) and necrotizing enterocolitis (NEC) are similar among indomethacin-exposed and nonexposed ELBW infants." | 3.73 | Combining phenobarbital and indomethacin to improve early neonatal outcomes in the extremely low birth weight infant. ( Ekekezie, II; Mundy, DC; Okah, FA, 2005) |
| "A retrospective study to compare the incidence of NEC, NEC-related gastrointestinal complications and isolated gastrointestinal perforation among premature infants treated for a PDA with either, indomethacin alone (I), surgical ligation alone (L), or indomethacin followed by surgical ligation (I-L)." | 3.72 | Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus. ( Adams, JM; Adams, K; Baetiong, A; Chen, A; O'Donovan, DJ; Smith, EO; Weisman, LE, 2003) |
| "Preterm infants with exposure to antenatal indomethacin might be at increased risk of grade I and II intraventricular haemorrhage and those with both ante- and postnatal exposure at an increased risk of necrotising enterocolitis and sepsis." | 3.70 | Perinatal indomethacin treatment and neonatal complications in preterm infants. ( Ikonen, S; Ojala, R; Tammela, O, 2000) |
| "Tocolysis with indomethacin as a single agent was not associated with necrotizing enterocolitis in this case-control study." | 3.70 | Indomethacin tocolysis and risk of necrotizing enterocolitis. ( Dooley, SL; Grobman, WA; Holtzman, RB; Parilla, BV; Thomas, HA, 2000) |
| "Indomethacin has been the standard treatment to close a PDA but is associated with renal, gastrointestinal, and cerebral side effects." | 2.66 | Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. ( Ohlsson, A; Shah, SS, 2020) |
| "Management of persistently patent ductus arteriosus (PDA) in extremely low-birth-weight infants (ELBWIs) requires attention due to the risk of tissue hypoperfusion." | 1.91 | Association between gastrointestinal perforation and patent ductus arteriosus in extremely-low-birth-weight infants: a retrospective study of our decade-long experience. ( Ibara, S; Ieiri, S; Ikee, T; Ikoma, S; Kawano, M; Kawano, T; Machigashira, S; Masuya, R; Matsukubo, M; Murakami, M; Muto, M; Nakame, K; Noguchi, H; Sugita, K; Torikai, M, 2023) |
| "(2) Multiple analyses showed that patent ductus arteriosus(PDA) (odds ratio[OR] = 5." | 1.91 | Patent ductus arterious and increased conjugated bilirubin in the second week after birth are independent risk factors for necrotizing enterocolitis in preterm infants: an observational study. ( Cui, S; Han, X, 2023) |
| "Symptomatic patent ductus arteriosus (sPDA) is the most common heart abnormality in preterm infants." | 1.62 | High Dose Indomethacin for Patent Ductus Arteriosus Closure Increases Neonatal Morbidity. ( Atkinson, A; Berger, MR; Gerull, R; Nelle, M; Waldvogel, S; Wilbeaux, M, 2021) |
| "Indomethacin has been administered for longer durations to prolong gestation in extreme prematurity." | 1.43 | Perinatal Outcomes after Short versus Prolonged Indomethacin for Tocolysis in Women with Preterm Labor. ( Behnia, F; Costantine, M; Dutta, EH; Harirah, H; Saade, G, 2016) |
| "The aim of this study is to compare patent ductus arteriosus (PDA) management strategies and outcomes between the Neonatal Research Network of Japan (NRNJ) with proactive functional echocardiography and the Canadian Neonatal Network (CNN) with selective conventional echocardiography practice." | 1.42 | Patent ductus arteriosus management and outcomes in Japan and Canada: comparison of proactive and selective approaches. ( Fujimura, M; Isayama, T; Kusuda, S; Lee, SK; Mirea, L; Mori, R; Shah, PS, 2015) |
| "Indomethacin has been also used in women with short cervices as well as in those with idiopathic polyhydramnios." | 1.38 | Indomethacin in pregnancy: applications and safety. ( Abou-Ghannam, G; Nassar, AH; Usta, IM, 2012) |
| "The effect of patent ductus arteriosus on necrotizing enterocolitis was assessed using multiple regression analysis." | 1.33 | Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. ( Dollberg, S; Lusky, A; Reichman, B, 2005) |
| " The total dosage was the same for both groups." | 1.33 | Continuous indomethacin infusion may be less effective than bolus infusions for ductal closure in very low birth weight infants. ( Bos, AF; de Vries, NK; Elzenga, NJ; Jaarsma, AS; Jagroep, FK, 2005) |
| "Indomethacin use has been implicated as a co-risk factor for SIP when combined with glucocorticoids, but previous evidence argued against indomethacin being an independent risk factor when used prophylactically." | 1.33 | New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure. ( Attridge, JT; Clark, R; Gordon, PV; Walker, MW, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.69) | 18.2507 |
| 2000's | 22 (37.29) | 29.6817 |
| 2010's | 25 (42.37) | 24.3611 |
| 2020's | 11 (18.64) | 2.80 |
| Authors | Studies |
|---|---|
| Hundscheid, T | 2 |
| Onland, W | 2 |
| Kooi, EMW | 2 |
| Vijlbrief, DC | 2 |
| de Vries, WB | 2 |
| Dijkman, KP | 2 |
| van Kaam, AH | 2 |
| Villamor, E | 2 |
| Kroon, AA | 2 |
| Visser, R | 2 |
| Mulder-de Tollenaer, SM | 2 |
| De Bisschop, B | 2 |
| Dijk, PH | 2 |
| Avino, D | 2 |
| Hocq, C | 2 |
| Zecic, A | 2 |
| Meeus, M | 2 |
| de Baat, T | 2 |
| Derriks, F | 2 |
| Henriksen, TB | 2 |
| Kyng, KJ | 2 |
| Donders, R | 2 |
| Nuytemans, DHGM | 2 |
| Van Overmeire, B | 2 |
| Mulder, AL | 2 |
| de Boode, WP | 2 |
| Muto, M | 1 |
| Sugita, K | 1 |
| Murakami, M | 1 |
| Ikoma, S | 1 |
| Kawano, M | 1 |
| Masuya, R | 1 |
| Matsukubo, M | 1 |
| Kawano, T | 1 |
| Machigashira, S | 1 |
| Nakame, K | 1 |
| Torikai, M | 1 |
| Ikee, T | 1 |
| Noguchi, H | 1 |
| Ibara, S | 1 |
| Ieiri, S | 1 |
| Clyman, RI | 2 |
| Hills, NK | 1 |
| Han, X | 1 |
| Cui, S | 1 |
| Xiong, T | 1 |
| Maheshwari, A | 1 |
| Neu, J | 1 |
| Ei-Saie, A | 1 |
| Pammi, M | 1 |
| Waldvogel, S | 1 |
| Atkinson, A | 1 |
| Wilbeaux, M | 1 |
| Nelle, M | 1 |
| Berger, MR | 1 |
| Gerull, R | 1 |
| Ohlsson, A | 5 |
| Shah, SS | 3 |
| Isayama, T | 2 |
| Kusuda, S | 2 |
| Reichman, B | 2 |
| Lee, SK | 4 |
| Lehtonen, L | 1 |
| Norman, M | 1 |
| Adams, M | 1 |
| Bassler, D | 1 |
| Helenius, K | 1 |
| Hakansson, S | 1 |
| Yang, J | 1 |
| Jain, A | 2 |
| Shah, PS | 5 |
| Gephart, SM | 1 |
| Underwood, MA | 1 |
| Rosito, S | 1 |
| Kim, JH | 1 |
| Caplan, MS | 1 |
| Mitra, S | 3 |
| Scrivens, A | 1 |
| von Kursell, AM | 1 |
| Disher, T | 1 |
| Evans, P | 1 |
| O'Reilly, D | 1 |
| Flyer, JN | 1 |
| Soll, R | 1 |
| Florez, ID | 1 |
| Tamayo, ME | 1 |
| Mbuagbaw, L | 1 |
| Vanniyasingam, T | 1 |
| Veroniki, AA | 1 |
| Zea, AM | 1 |
| Zhang, Y | 1 |
| Sadeghirad, B | 1 |
| Thabane, L | 1 |
| Nair, J | 1 |
| Lakshminrusimha, S | 1 |
| Walia, R | 2 |
| Li, D | 1 |
| Rosito, G | 1 |
| Slagle, T | 1 |
| Hammers, AL | 2 |
| Sanchez-Ramos, L | 2 |
| Kaunitz, AM | 2 |
| Kirtsman, M | 1 |
| Yoon, EW | 1 |
| Ojah, C | 1 |
| Cieslak, Z | 1 |
| Mirea, L | 2 |
| Mori, R | 1 |
| Fujimura, M | 1 |
| Hallman, M | 1 |
| Pesonen, E | 1 |
| Teramo, K | 1 |
| Faucett, AM | 1 |
| Metz, TD | 1 |
| DeWitt, PE | 1 |
| Gibbs, RS | 1 |
| Chen, Y | 1 |
| Chang, KT | 1 |
| Lian, DW | 1 |
| Lu, H | 1 |
| Roy, S | 1 |
| Laksmi, NK | 1 |
| Low, Y | 1 |
| Krishnaswamy, G | 1 |
| Pierro, A | 1 |
| Ong, CC | 1 |
| Louis, D | 1 |
| Torgalkar, R | 1 |
| Shah, J | 1 |
| Dutta, EH | 1 |
| Behnia, F | 1 |
| Harirah, H | 1 |
| Costantine, M | 1 |
| Saade, G | 1 |
| Haw, MP | 1 |
| Talavera, MM | 1 |
| Bixler, G | 1 |
| Cozzi, C | 1 |
| Dail, J | 1 |
| Miller, RR | 1 |
| McClead, R | 1 |
| Reber, K | 1 |
| Prescott, S | 1 |
| Keim-Malpass, J | 1 |
| Gordon, PV | 2 |
| Swanson, JR | 1 |
| Clark, R | 2 |
| Sharma, R | 1 |
| Hudak, ML | 1 |
| Tepas, JJ | 1 |
| Wludyka, PS | 1 |
| Teng, RJ | 1 |
| Hastings, LK | 1 |
| Renfro, WH | 1 |
| Marvin, WJ | 1 |
| El-Khuffash, AF | 1 |
| McNamara, PJ | 1 |
| Sood, BG | 1 |
| Lulic-Botica, M | 1 |
| Holzhausen, KA | 1 |
| Pruder, S | 1 |
| Kellogg, H | 1 |
| Salari, V | 1 |
| Thomas, R | 1 |
| Abou-Ghannam, G | 1 |
| Usta, IM | 1 |
| Nassar, AH | 1 |
| Saldeño, YP | 1 |
| Favareto, V | 1 |
| Mirpuri, J | 1 |
| Sankaran, K | 1 |
| Seshia, M | 1 |
| Allen, AC | 1 |
| Aziz, K | 1 |
| Lee, CH | 1 |
| Chen, HN | 1 |
| Tsao, LY | 1 |
| Hsiao, CC | 1 |
| Lee, ML | 1 |
| Sivanandan, S | 1 |
| Bali, V | 1 |
| Soraisham, AS | 1 |
| Harabor, A | 1 |
| Kamaluddeen, M | 1 |
| Hwang, H | 1 |
| Murphy, JJ | 1 |
| Gow, KW | 1 |
| Magee, JF | 1 |
| Bekhit, E | 1 |
| Jamieson, D | 1 |
| O'Donovan, DJ | 1 |
| Baetiong, A | 1 |
| Adams, K | 1 |
| Chen, A | 1 |
| Smith, EO | 1 |
| Adams, JM | 1 |
| Weisman, LE | 1 |
| Lee, J | 1 |
| Rajadurai, VS | 1 |
| Tan, KW | 1 |
| Wong, KY | 1 |
| Wong, EH | 1 |
| Leong, JY | 1 |
| Okah, FA | 1 |
| Mundy, DC | 1 |
| Ekekezie, II | 1 |
| Dollberg, S | 1 |
| Lusky, A | 1 |
| de Vries, NK | 1 |
| Jagroep, FK | 1 |
| Jaarsma, AS | 1 |
| Elzenga, NJ | 1 |
| Bos, AF | 1 |
| Doyle, NM | 1 |
| Gardner, MO | 1 |
| Wells, L | 1 |
| Qualls, C | 1 |
| Papile, LA | 1 |
| Attridge, JT | 1 |
| Walker, MW | 1 |
| Bloom, BT | 1 |
| Patole, SK | 1 |
| Kumaran, V | 1 |
| Travadi, JN | 1 |
| Brooks, JM | 1 |
| Doherty, DA | 1 |
| Pietz, J | 1 |
| Achanti, B | 1 |
| Lilien, L | 1 |
| Stepka, EC | 1 |
| Mehta, SK | 1 |
| Kawase, Y | 1 |
| Ishii, T | 1 |
| Arai, H | 1 |
| Uga, N | 1 |
| Warner, BB | 1 |
| Ryan, AL | 1 |
| Seeger, K | 1 |
| Leonard, AC | 1 |
| Erwin, CR | 1 |
| Warner, BW | 1 |
| Fakhraee, SH | 1 |
| Badiee, Z | 1 |
| Mojtahedzadeh, S | 1 |
| Kazemian, M | 1 |
| Kelishadi, R | 1 |
| Amin, SB | 1 |
| Sinkin, RA | 1 |
| Glantz, JC | 1 |
| Madan, J | 1 |
| Fiascone, J | 1 |
| Balasubramanian, V | 1 |
| Griffith, J | 1 |
| Hagadorn, JI | 1 |
| Narayanan, M | 1 |
| Schlueter, M | 1 |
| Kamitsuka, MD | 1 |
| Horton, MK | 1 |
| Williams, MA | 1 |
| Ojala, R | 1 |
| Ikonen, S | 1 |
| Tammela, O | 1 |
| Parilla, BV | 1 |
| Grobman, WA | 1 |
| Holtzman, RB | 1 |
| Thomas, HA | 1 |
| Dooley, SL | 1 |
| Adamska, E | 1 |
| Schmidt, B | 1 |
| Davis, P | 1 |
| Moddemann, D | 1 |
| Roberts, RS | 1 |
| Saigal, S | 1 |
| Solimano, A | 1 |
| Vincer, M | 1 |
| Wright, LL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-center, Randomized Non-inferiority Trial of Early Treatment Versus Expectative Management of Patent Ductus Arteriosus in Preterm Infants (BeNeDuctus Trial - Belgium Netherlands Ductus Trial)[NCT02884219] | 273 participants (Actual) | Interventional | 2016-12-23 | Completed | |||
| Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI)[NCT01630278] | Phase 3 | 363 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Open Label, Controlled Trial[NCT03022253] | Phase 3 | 44 participants (Anticipated) | Interventional | 2016-03-31 | Completed | ||
| RIC-NEC Phase II Feasibility Randomized Controlled Trial: Remote Ischemic Conditioning in Necrotizing Enterocolitis[NCT05279664] | Phase 2 | 78 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus in Premature Infants: A Pilot Study[NCT03103022] | Phase 1 | 20 participants (Actual) | Interventional | 2017-06-12 | Completed | ||
| Randomized, Placebo Controlled Trial of Indomethacin for Tocolysis[NCT01869361] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-08-01 | Withdrawn (stopped due to Due to much lower than expected numbers of eligible patients and lack of PI time, the study was not started.) | ||
| Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants[NCT00063063] | 80,000 participants (Anticipated) | Observational | 1987-01-31 | Recruiting | |||
| Intestinal Function in Neonates With Complex Congenital Heart Disease[NCT01475357] | 27 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
| Collaborative Research Group for Necrotizing Enterocolitis[NCT00828451] | 29 participants (Actual) | Interventional | 2008-05-31 | Completed | |||
| Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)[NCT00009646] | Phase 3 | 1,202 participants (Actual) | Interventional | 1993-11-30 | Completed | ||
| High-Dose Erythropoietin in Very Low Birth Weight Infants for the Potential Treatment of Prematurity-Related Cerebral Hemorrhagic-Ischemic Injury: A Phase II Safety/Tolerability Study[NCT00589953] | Phase 2 | 22 participants (Actual) | Interventional | 2007-07-31 | Terminated | ||
| Follow-up Visit of High Risk Infants[NCT00009633] | 68,000 participants (Anticipated) | Observational | 1993-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Identification of computationally predicted functional variants in EGF gene (NCT00828451)
Timeframe: Sampling occurred on average day of life 9 with a range from day of life 7 to 21
| Intervention | percentage of participants with variant (Number) |
|---|---|
| Preterm Infants for EGF Profiles | 11 |
Salivary EGF protein levels obtained from oral swabs were analyzed by commercially available EGF ELISA kit (R &D systems Inc). EGF protein levels were normalized to micrograms of protein in saliva, and expressed as picogram of EGF protein per microgram of total salivary protein. (NCT00828451)
Timeframe: Sampling occurred on average day of life 9 with a range from day of life 7 to 21
| Intervention | picograms EGF/ microgram of protein (Median) |
|---|---|
| Preterm Infants for EGF Profiles | 15 |
Urinary EGF protein levels obtained from free flowing urine samples retrieved from subject diaper were analyzed by commercially available EGF ELISA kit (R &D systems Inc). EGF protein levels were normalized to milligrams of creatinine in urine, and expressed as nanograms of EGF protein per milligram of urinary creatinine. (NCT00828451)
Timeframe: Sampling occurred on average day of life 9 with a range from day of life 7 to 21
| Intervention | nanograms of EGF/mg of creatinine (Median) |
|---|---|
| Preterm Infants for EGF Profiles | 48 |
14 reviews available for indomethacin and Necrotizing Enterocolitis
| Article | Year |
|---|---|
An Overview of Systematic Reviews of Randomized-Controlled Trials for Preventing Necrotizing Enterocolitis in Preterm Infants.
Topics: Administration, Oral; Adrenal Cortex Hormones; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing | 2020 |
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Drug-Related Side Effects and Adverse Reactions; Duc | 2020 |
Grading the evidence to identify strategies to modify risk for necrotizing enterocolitis.
Topics: Adrenal Cortex Hormones; Anemia; Anti-Bacterial Agents; Ductus Arteriosus, Patent; Enterocolitis, Ne | 2020 |
Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Cerebral Intraventricular Hemorrhage; Chron | 2020 |
Indomethacin for symptomatic patent ductus arteriosus in preterm infants.
Topics: Bias; Bronchopulmonary Dysplasia; Cause of Death; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pate | 2021 |
Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.
Topics: Acetaminophen; Administration, Intravenous; Administration, Oral; Bayes Theorem; Cerebral Hemorrhage | 2018 |
Role of NO and other vascular mediators in the etiopathogenesis of necrotizing enterocolitis.
Topics: Age of Onset; Animals; Arginine; Catecholamines; Disease Models, Animal; Dogs; Endothelins; Enteroco | 2019 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; | 2013 |
Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis.
Topics: Cerebral Ventricles; Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Infant, Newborn; Infa | 2015 |
Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enterocolitis, Necrotizi | 2015 |
Surgical Intervention in Preterm Neonates with Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Combined Modality Therapy; Cyclooxygenase Inhibitors; Ductus Arteriosus, | 2016 |
Patent Ductus Arteriosus in the Preterm Infant: Diagnostic and Treatment Options.
Topics: Biomarkers; Cardiac Catheterization; Conservative Treatment; Cyclooxygenase Inhibitors; Ductus Arter | 2017 |
Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes.
Topics: Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant | 2007 |
[Ibuprofen--a new application for pharmacological closure of patent ductus arteriosus in preterm infants. Preliminary report].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Clinical Trials as Topic; Ductu | 2000 |
4 trials available for indomethacin and Necrotizing Enterocolitis
| Article | Year |
|---|---|
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Ductus Arteriosus, Patent; Ec | 2003 |
Comparison of oral ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants.
Topics: Administration, Oral; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; Indo | 2007 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants.
Topics: Blindness; Cerebral Palsy; Cognition Disorders; Ductus Arteriosus, Patent; Enterocolitis, Necrotizin | 2001 |
41 other studies available for indomethacin and Necrotizing Enterocolitis
| Article | Year |
|---|---|
Association between gastrointestinal perforation and patent ductus arteriosus in extremely-low-birth-weight infants: a retrospective study of our decade-long experience.
Topics: Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Humans; Ibuprofen; Indomethacin; Infant, Extr | 2023 |
Prophylactic indomethacin, antenatal betamethasone, and the risk of intestinal perforation in infants <28 weeks' gestation.
Topics: Betamethasone; Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Infant; Infant, Newborn; In | 2023 |
Patent ductus arterious and increased conjugated bilirubin in the second week after birth are independent risk factors for necrotizing enterocolitis in preterm infants: an observational study.
Topics: Bilirubin; Child; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Female; Fetal Diseases; Hum | 2023 |
High Dose Indomethacin for Patent Ductus Arteriosus Closure Increases Neonatal Morbidity.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arte | 2021 |
Neonatal Intensive Care Unit-Level Patent Ductus Arteriosus Treatment Rates and Outcomes in Infants Born Extremely Preterm.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Canada; Cardiovascular Surgical Procedures; Cerebral | 2020 |
Probiotics for the prevention of necrotizing enterocolitis in neonates: an 8-year retrospective cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Breast Feeding; Cohort Studies; Ductus Arteri | 2013 |
Nil-per-os days and necrotizing enterocolitis in extremely preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Canada; Case-Control Studies; Ductus Arteriosus, Patent; En | 2015 |
Patent ductus arteriosus management and outcomes in Japan and Canada: comparison of proactive and selective approaches.
Topics: Bronchopulmonary Dysplasia; Canada; Cerebral Hemorrhage; Comorbidity; Cyclooxygenase Inhibitors; Duc | 2015 |
Reply: To PMID 25448524.
Topics: Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Intracranial Hemorrhages; Leukomalacia, Pe | 2015 |
Indomethacin as a tocolytic harmful to preterm infant.
Topics: Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Intracranial Hemorrhages; Leukomalacia, Pe | 2015 |
Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Birth Weight; Case-Control Studies; Cerebral Hemorrhage; | 2016 |
The role of ischemia in necrotizing enterocolitis.
Topics: Age of Onset; Biomarkers; Enterocolitis, Necrotizing; Glucose Transporter Type 1; Humans; Hypoxia; H | 2016 |
Enteral feeding during indomethacin treatment for patent ductus arteriosus: association with gastrointestinal outcomes.
Topics: Birth Weight; Canada; Ductus Arteriosus, Patent; Enteral Nutrition; Enterocolitis, Necrotizing; Fema | 2016 |
Perinatal Outcomes after Short versus Prolonged Indomethacin for Tocolysis in Women with Preterm Labor.
Topics: Adult; Drug Administration Schedule; Enterocolitis, Necrotizing; Female; Gestational Age; Humans; In | 2016 |
Quality Improvement Initiative to Reduce the Necrotizing Enterocolitis Rate in Premature Infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Transfusion; Enterocolitis, Necrotizing; Humans; Inci | 2016 |
Antenatal indomethacin is more likely associated with spontaneous intestinal perforation rather than NEC.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Enterocolitis, Necrotizing; Humans; Indomethacin; Intestina | 2008 |
Prenatal or postnatal indomethacin exposure and neonatal gut injury associated with isolated intestinal perforation and necrotizing enterocolitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cerebral Ventricles; Drug Administrati | 2010 |
The patent ductus arteriosus ligation decision.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; Huma | 2011 |
The risk of necrotizing enterocolitis after indomethacin tocolysis.
Topics: Cohort Studies; Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Infant, Newborn; Infant, P | 2011 |
Indomethacin in pregnancy: applications and safety.
Topics: Cerclage, Cervical; Cerebral Hemorrhage; Ductus Arteriosus; Enterocolitis, Necrotizing; Female; Fetu | 2012 |
Prolonged persistent patent ductus arteriosus: potential perdurable anomalies in premature infants.
Topics: Analysis of Variance; Bronchopulmonary Dysplasia; Cardiac Surgical Procedures; Case-Control Studies; | 2012 |
Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias.
Topics: Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Comorbidity; Cyclooxygenase Inhibitors; Ductus Arte | 2012 |
Oral ibuprofen versus intravenous indomethacin for closure of patent ductus arteriosus in very low birth weight infants.
Topics: Administration, Intravenous; Administration, Oral; Ductus Arteriosus, Patent; Enterocolitis, Necroti | 2012 |
Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Fema | 2013 |
Are localized intestinal perforations distinct from necrotizing enterocolitis?
Topics: Adult; Catheterization; Dexamethasone; Diagnosis, Differential; Enterocolitis, Necrotizing; Female; | 2003 |
Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus.
Topics: Birth Weight; Cardiac Surgical Procedures; Cardiovascular Agents; Ductus Arteriosus, Patent; Enteroc | 2003 |
Combining phenobarbital and indomethacin to improve early neonatal outcomes in the extremely low birth weight infant.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Drug Therapy, Combination; Enterocolitis, | 2005 |
Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Female; Humans; Indome | 2005 |
Continuous indomethacin infusion may be less effective than bolus infusions for ductal closure in very low birth weight infants.
Topics: Cardiovascular Agents; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration S | 2005 |
Outcome of very low birth weight infants exposed to antenatal indomethacin for tocolysis.
Topics: Cause of Death; Cohort Studies; Critical Care; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing | 2005 |
New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Databases, Factual; E | 2006 |
Attridge et al. present an analysis of a complex data set, which offers important confirmation of the differences between the clinical presentation of spontaneous intestinal perforations (SIP) and surgical necrotizing enterocolitis (NEC).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Enterocolitis, Necrotizing; Humans | 2006 |
Does patent ductus arteriosus affect feed tolerance in preterm neonates?
Topics: Age Factors; Analysis of Variance; Cardiovascular Agents; Ductus Arteriosus, Patent; Enteral Nutriti | 2007 |
Prevention of necrotizing enterocolitis in preterm infants: a 20-year experience.
Topics: Dexamethasone; Enterocolitis, Necrotizing; Feeding Methods; Female; Humans; Indomethacin; Infant, Ex | 2007 |
Gastrointestinal perforation in very low-birthweight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Enterocolitis, Necrotizing; Female | 2006 |
Ontogeny of salivary epidermal growth factor and necrotizing enterocolitis.
Topics: Age Factors; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Apgar Score; Cohort Stu | 2007 |
Predictors of ductal closure and intestinal complications in very low birth weight infants treated with indomethacin.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Female; Humans; Indome | 2008 |
Incidence and outcome of a 10-fold indomethacin overdose in premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Ductus Art | 1999 |
The incidence of necrotizing enterocolitis after introducing standardized feeding schedules for infants between 1250 and 2500 grams and less than 35 weeks of gestation.
Topics: Birth Weight; Cohort Studies; Enterocolitis, Necrotizing; Feeding Methods; Female; Humans; Indometha | 2000 |
Perinatal indomethacin treatment and neonatal complications in preterm infants.
Topics: Cerebral Hemorrhage; Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Infant, Newborn; Infa | 2000 |
Indomethacin tocolysis and risk of necrotizing enterocolitis.
Topics: Adult; Case-Control Studies; Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Infant, Newbo | 2000 |